Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

How I treat newly diagnosed chronic myeloid leukemia in 2015

(2014) Carlo Gambacorti-Passerini et al.   AMERICAN JOURNAL OF HEMATOLOGY

First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis

(2014) Ilaria Viganò et al.   AMERICAN JOURNAL OF HEMATOLOGY

Differences among young adults, adults and elderly chronic myeloid leukemia patients

(2014) F. Castagnetti et al.   ANNALS OF ONCOLOGY

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?

(2014) Johan Richter et al.   JOURNAL OF CLINICAL ONCOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

(2012) Ho-Young Yhim et al.   LEUKEMIA RESEARCH

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

(2011) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

(2011) N. Takahashi et al.   HAEMATOLOGICA

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

(2011) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

(2009) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

(2009) Salvatore Guastafierro et al.   LEUKEMIA RESEARCH